Published: 2019-01-25

Role of Ki67 protein in colorectal cancer

I Made Mulyawan


Colorectal cancer has become one of the most frequent malignancy and the leading cause of death from cancer globally. Global Burden Cancer in 2013 had placed colorectal cancer in third place morbidity level and forth most lethal cancer globally. Understanding prognostic marker is essential to increase prognosis prediction in patients with colorectal cancer, especially in patient with the later stages. Several studies have reported the prognostic value of Ki67 expression in patient with colorectal cancer. Ki67 protein expression is associated with proliferative activation from intrinsic cell population in malignant tumor cells, where Ki67 can be used as a marker for tumor aggressivity. Expressions from protein Ki67 are associated with proliferative activities from intrinsic cell population in malignant tumor cells, where Ki67 can be used as marker from tumor cell’s aggressivity. Several diagnostic applications for pKi67 has already been explained, where Ki67 is significantly higher in malignancy compared to normal tissue. pKi67 is also increased along with the decrease of tissue differentiation, and it correlates with the presence of metastasis that can not be seen and tumor clinical phase. Prognostic value from Ki67 had been investigated in many studies with their potential as reliable marker in breasts, soft tissue, lungs, prostate, cervix, and central nervous system. Positive expression from Ki67 in colorectal cancer shows a better prognosis in patient who received surgical treatment and adjuvant radiochemotherapy, but not in a patient who received only a surgical treatment.


Colorectal cancer, Diagnostic, Expression of protein, Function, Ki67 protein, Prognostic

Full Text:



Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;192:311-22.

Modlin IM, Moss SF, Chung DC, Jensen RT, Snyderwine E. Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst. 2008;100:1282-9.

Klöppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci. 2004;1014:13‑27.

Ishihara M, Mukai H, Nagai S, Onozawa M, Nihei K, Shimada T, et al. Retrospective analysis of risk factors for central nervous system metastases in operable breast cancer: effects of biologic subtype and Ki67 overexpression on survival. Oncology. 2013;84:135‑40.

Sorbye SW, Kilvaer TK, Valkov A, Donnem T, Smeland E, Al-Shibli K, et al. Prognostic Impact of Jab1, p16, p21, p62, Ki67 and Skp2 in Soft Tissue Sarcomas. PLoS ONE. 2012;7:e47068.

Li P, Xiao ZT, Braciak TA, Ou QJ, Chen G, Oduncu FS. Association between Ki67 Index and Clinicopathological Features in Colorectal Cancer. Oncol Res Treat. 2016;39:696-702.

Li LT, Jiang G, Chen Q, Zheng JN. Ki67 is a promising molecular target in the diagnosis of cancer (Review). Mol Med Rep. 2015;11:1566-72.

Sohal DPS, Kuderer NM, Shepherd FA, Pabinger I, Agnelli G, Liebman HA, et al. Clinical predictors of early mortality in colorectal cancer patients undergoing chemotherapy: results from a global prospective cohort study. JNCI J Natl Cancer Inst 2017;1:pkx009.

Milinis K, Thornton M, Montazeri A, Rooney PS. Adjuvant chemotherapy for rectal cancer: Is it needed?. World J Clin Oncol. 2015;6:225-36.

Iatropoulos MJ, Williams GM. Proliferation markers. Exp Toxicol Pathol. 1996;48:175-81.

Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010;11:174‑83.

Duchrow M, Schlüter C, Wohlenberg C, Flad HD, Gerdes J. Molecular characterization of the gene locus of the human cell proliferation-associated nuclear protein defined by monoclonal antibody Ki-67. Cell Prolif. 1996;29:1-12.

Sysel AM, Valli VE, Bauer JA. Immunohistochemical quantification of the cobalamin transport protein, cell surface receptor and Ki-67 in naturally occurring canine and feline malignant tumors and in adjacent normal tissues. Oncotarget. 2015;6:2331-48.

Panteva MT, Salari R, Bhattacharjee M, Chong LT. Direct observations of shifts in the β-sheet register of a protein-peptide complex using explicit solvent simulations. Biophys J. 2011;100:L50-2.

Bădulescu F, Mihai GM, Bădulescu A, Prejbeanu I. Histoprognostic markers role in colorectal cancer. Rom J Morphol Embrryol. 2016;57:445-50.

Aunan JR, Cho WC, Søreide K. The Biology of Aging and Cancer: A Brief Overview of Shared and Divergent Molecular Hallmarks. Aging Dis. 2017;8:628-42.

Martin B, Paesmans M, Mascaux C, Berghmans T, Lothaire P, Meert AP, et al. Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer. 2004;91:2018-25.

Hayashi Y, Takei H, Kurosumi M. Ki67 immunohistochemical staining: the present situation of diagnostic criteria. Nihon Rinsho. 2012;70:428-32.

Geyer FC, Rodrigues DN, Weigelt B, Reis Filho JS. Molecular classification of estrogen receptor positive/luminal breast cancers. Adv Anat Pathol. 2012;19:39 53.

Lind‑Landström T, Habberstad AH, Sundstrøm S, Torp SH. Prognostic value of histological features in diffuse astrocytomas WHO grade II. Int J Clin Exp Pathol. 2012;5:152‑8.

Yu JY, DeRuiter SL, Turner DL. RNA interference by expression of short interfering RNAs and hairpin RNAs in mammalian cells. Proc Natl Acad Sci USA. 2002;99:6047 52.

Chen JX, Deng N, Chen X, Chen LW, Qiu SP, Li XF, et al. A novel molecular grading model: combination of Ki67 and VEGF in predicting tumor recurrence and progression in non‑invasive urothelial bladder cancer. Asian Pac J Cancer Prev. 2012;13:2229‑34.

Xiong DD, Lin XG, He RQ, Pan DH, Luo YH, Dang YW, et al. Ki67/MIB-1 predict better prognoses in colorectal cancer patients received both surgery and adjuvant radio-chemotherapy: a meta-analysis of 30 studies. Int J Clin Exp Med. 2017;10:1788-804.

Vogt N, Klapper W. Variability in morphology and cell proliferation in sequential biopsies of mantle cell lymphoma at diagnosis and relapse: clinical correlation and insights into disease progression. Histopathology. 2013;62:334-42.

Weber JC, Nakano H, Bachellier P, Oussoultzoglou E, Inoue K, Shimura H, et al. Is a proliferation index of cancer cells a reliable prognostic factor after hepatectomy in patients with colorectal liver metastases?. Am J Surg. 2001;182:81-8.

Handa K, Yamakawa M, Takeda H, Kimura S,Takahashi T. Expression of cell cycle markers in colorectal carcinoma: superiority of cyclin A as an indicator of poor prognosis. Int J Cancer. 1999;84:225-33.

Fluge Ø, Gravdal K, Carlsen E, Vonen B, Kjellevold K, Refsum S, et al. Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment respone and prognosis. Br J Cancer. 2009;101:1282-9.

Melling N, Kowitz CM, Simon R, Bokemeyer C, Terracciano L, Sauter G, et al. High Ki67 expression is an independent good prognostic marker in colorectal cancer. J Clin Pathol. 2016;69:209-14.

Itamochi H, Kigawa J, Sugiyama T, Kikuchi Y, Suzuki M, Terakawa N. Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol. 2002;100:281-7.